🔗 Share this article

The recently developed medications for gonorrhoea in many years are being described as a "major milestone" in the fight against drug-resistant strains of the pathogen, according to researchers.

A Global Challenge

Cases of gonorrhoea are escalating globally, with estimates suggesting in excess of 82 million infections per year. Particularly high rates are seen in Africa and countries within the WHO's Western Pacific region, which includes China and Mongolia to New Zealand. Within England, cases have hit a historical peak, while rates across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an important and timely step in the context of increasing worldwide cases, the spread of superbugs and the very limited therapeutic options presently on offer.”

Public health authorities are particularly alarmed about the increase in drug-resistant strains. The WHO has listed it as a "high-priority threat". Ongoing monitoring revealed that resistance to key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Therapies Gain Clearance

Zoliflodacin, marketed under the name Nuzolvence, was cleared by the US FDA in December for combating gonorrhoea. This STI can lead to major issues, including infertility. Researchers hope that focused deployment of this new drug will help delay the spread of drug resistance.

Gepotidacin, created by the drugmaker GlaxoSmithKline, gained clearance in concurrent days. This medication, which is also used to treat UTIs, was proven in research to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment was the result of a unique collaborative effort for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to see it through.

“This approval marks a major breakthrough in the treatment of superbug gonorrhoea, which up to this point has been staying ahead of medical innovation.”

Research Study Data and Global Access

According to findings released by a prominent scientific publication, the new drug eradicated the vast majority of uncomplicated infections. This places it at an comparable level with the current standard treatment, which combines an injection and a pill. The trial involved nearly 1,000 patients from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, the non-profit has the rights to license and sell the drug in numerous developing nations.

Clinicians on the front lines have expressed hope. The availability of a easy-to-administer therapy like this is seen as a "game-changer" for gonorrhoea control. This is deemed essential to lessen the impact of the illness for individuals and to stop the proliferation of untreatable gonorrhoea globally.